NCT05684770 Impact of Remote Care in Patients Diagnosed With Thromboembolic Disease of Low Risk
| NCT ID | NCT05684770 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Eure-Seine |
| Condition | Thromboembolic Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-09 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2025-09 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn about the feasibility and impact of remote care in patients diagnosed with thromboembolic disease of low risk. The main questions it aims to answer are: * the evaluation of feasibility of organisation between different healthcare professionals (hospital physicians, primary care physician) at 6 months and 1 year * the evaluation of complication rate, hospitalisation related to thromboembolic disease rate, compliance to treatment rate at 6 months and 1 year Participants will receive indication of treatment according to national recommendations. Additionnally, they will receive for the length of study a 4G tablet in order to fill questionnaires, learn information about their drugs (patient education), have a remote consultation and evaluate treatment compliance.
Eligibility Criteria
Inclusion Criteria: * patients identified in the emergency department with a thromboembolic disease, with a deep vein thrombosis or pulmonary embolism with a low risk of mortality according to recommendations * affiliated or beneficiary of social protection Exclusion Criteria: * patient having a severe obstruction syndrome, a thromboembolic disease already under treatment or a suspicion of thrombocytopenia induced by heparin * patient with an active hemorrhage or a major risk of hemorrhage, a renal severe failure, comorbidities such as cancer, or the impossibility to organise a consultation or a patient in a non favorable medico-social context * patient with a caval thrombosis * patient suffering of a disease at hemorrhagic risk or neurosurgery intervention done in the last month or other surgery in the last 15 days prior to inclusion * patient with contraindication of direct oral anticoagulants, such as bitherapy with antiplatelet agent, imidazoles, macrolides, antiretroviral treatments or an anti-phospholipid syndrome * patient that lives in an area not covered by internet * patient that has no primary care physician * patient not able to understand the study (language, psychological problem) or not able to read or write * patient under legal protection
Contact & Investigator
Vincent Eble, MD
PRINCIPAL INVESTIGATOR
CH Eure-Seine
Frequently Asked Questions
Who can join the NCT05684770 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Thromboembolic Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05684770 currently recruiting?
Yes, NCT05684770 is actively recruiting participants. Contact the research team at arc2.circe@ch-eureseine.fr for enrollment information.
Where is the NCT05684770 trial being conducted?
This trial is being conducted at Évreux, France.
Who is sponsoring the NCT05684770 clinical trial?
NCT05684770 is sponsored by Centre Hospitalier Eure-Seine. The principal investigator is Vincent Eble, MD at CH Eure-Seine. The trial plans to enroll 50 participants.